Basilea Secures $268M BARDA Funding for Antifungal and Antibacterial Development

Funding Agreement:
Basilea has entered into a $268 million agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop antifungals and antibacterials.

Development Focus:
The funding will support the development of treatments against fungal and bacterial infections, addressing critical public health needs.

Partnership Impact:
This partnership underscores the importance of public-private collaborations in advancing medical research and development, particularly in areas of high unmet need.

Company Background:
Basilea is a biopharmaceutical company that focuses on developing innovative treatments for serious and potentially life-threatening diseases.

BARDA's Role:
BARDA, part of the U.S. Department of Health and Human Services, provides funding and support for the development of medical countermeasures against bioterrorism threats and emerging infectious diseases.